Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New appointment at Versartis

This article was originally published in Scrip

Executive Summary

Versartis (US), an emerging biotechnology company developing therapeutics for metabolic diseases and endocrine disorders, has appointed Paul Westberg senior vice-president of business development. He was most recently vice-president of business development at Bayhill Therapeutics, and has also worked at Collabra Pharma, Deltagen and Genentech. Versartis is planning to initiate its first clinical trial of its lead product candidate VRS-859 in type 2 diabetes in the second half and to have top-line results by the end of the year.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC008418

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel